Legal Disclaimer

The Bar Council of India does not permit advertisement or solicitation by advocates in any form or manner.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Rahul Chaudhry & Partners (“the Firm”, “we”, “our” or “us”) of your own accord and that there has been no form of solicitation, advertisement or inducement by the Firm or any of its members.

The content of this website is provided solely for general informational purposes and is intended to provide information about the Firm, its practice areas, professionals, publications and legal developments. Nothing contained on this website should be construed as legal advice, legal opinion or a substitute for obtaining professional legal advice.

All the content on this website, including text, publications, graphics, logos and other materials, is the intellectual property of Rahul Chaudhry & Partners and may not be reproduced, distributed or used without the Firm’s prior written permission.

Your use of this website is also governed by our Privacy Policy and Terms of Use. 

 

July 2026 – Rahul Chaudhry & Partners

Novartis Succeeds in Patent Infringement Lawsuits Related to Vidagliptin.

Novartis had filed multiple qua timet patent infringement lawsuits against a number of generic companies including Biocon, Glenmark, Wockhardt Ajanta Pharma etc. and has managed to secure several interim injunctions against these generic companies. In 37 of these infringement lawsuits, Novartis either secured an interim injunction or a settlement from the defendant making this series

CATEGORIES

ARCHIVES

Do you need professional legal assistance?